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Sigma (σ) receptor ligands are essentially known for their effects on the nervous system
although recent studies have shown their potential effects modulating some other patho-
physiological processes as cell proliferation, cancer, and the immune response. Here, we
have analyzed the actions of σ-1 and σ-2 receptors ligands on T cell activation. Our results
show that treatment of Jurkat T cells with σ-2 agonists decreased the induction of the
expression of Interleukin (IL)-2,Tumor necrosis factor (TNF)-α, and Cyclooxygenase (COX)-2
by activated T cells in a dose-dependent manner. These effects take place at the transcrip-
tional level since σ-2 agonists BD-737 and CB-184 diminished the activity of the promoters
of those genes. Those immunosuppressive effects could be attributable to interference
with transcription factor activation. Induced transcription mediated by Nuclear factor (NF)-
κB or Nuclear Factor of ActivatedT cells (NFAT) was inhibited by σ-2 agonists.These effects
seem to be specific for σ-2 agonists as no significant effects onT cell activation by σ-1 ligands
PRE-084 and BD-1063 were found. Our results provide new insights into the immunomod-
ulatory actions of σ ligands and describe a new property of σ-2 agonists, through inhibition
of activation of transcription factors as NFAT by which these compounds are regulating
gene expression. This may have important consequences on the possible therapeutic use
of those compounds.
Keywords: T lymphocytes, sigma receptor, transcriptional regulation, nuclear factor of activated T cells, nuclear
factor-κB
INTRODUCTION
Sigma (σ) receptors were originally identified as members of the
family of opioid receptors. Pharmacological studies have identi-
fied two subtypes of σ receptors, named σ-1 and σ-2 (reviewed in;
Bowen, 2000; Su and Hayashi, 2003; Guitart et al., 2004). However,
their endogenous ligands still remains unknown. Moreover, it has
not been well defined which are the signal transduction pathways
triggered by those receptors. Whereas the gene encoding the σ-1
receptor has been cloned and characterized (Hanner et al., 1996),
the molecular nature of the σ-2 receptor is still not clearly defined.
A recent report has identified the progesterone receptor mem-
brane component 1 (PGRMC1) protein as the putative sigma-2
receptor (Xu et al., 2011). Sigma receptor ligands have been widely
investigated for the treatment of brain related disorders (Bowen,
2000; Guitart et al., 2004) although recent studies have attributed
to σ-1 and σ-2 ligands a therapeutic role in other pathologies as
inflammatory diseases and cancer (Bourrie et al., 2004; Megalizzi
et al., 2010; van Waarde et al., 2010).
Abbreviations: COX, Cyclooxygenase; CsA, Cyclosporin A; Ion, A23187 calcium
ionophore; FBS, fetal bovine serum; GAPDH, glyceraldehyde 3 phosphate dehy-
drogenase; IL, interleukin; Luc, luciferase; NFAT, nuclear factor of activated T cells;
NFκB, nuclear factor κB; PBTs, peripheral blood T lymphocytes; PG, prostaglandin;
PMA, phorbol 12-myristate 13-acetate; SD, standard deviation; TCR, T cell receptor;
TNF tumor necrosis factor.
These receptors are mainly expressed in a variety of distinct
regions of the central nervous system but recent reports have also
shown significant levels of sigma receptors in immune tissues.
Thus, high-affinity σ receptors have been identified in human
peripheral blood mononuclear cells (Su et al., 1988; Wolfe et al.,
1988) and rat and mouse spleen (Carr et al., 1991; Liu et al.,
1995) using selective radio-ligands. Although involvement of σ
receptors in the regulation of inflammation and the immune
response have been reported, few studies have addressed the
selective effect of σ-1 and σ-2 ligands (either agonists or antag-
onists) on immune function so far. Most of the studies have
been performed with dual σ-1 and σ-2 ligands, as SR31747,
which binds with high-affinity to human and rat leukocytes
and exhibit immunosuppressive properties in vitro and in vivo.
This ligand suppresses mitogen-induced proliferation of mouse
and human lymphocytes (Casellas et al., 1994) and stimulates
LPS- or staphylococcal enterotoxin B-induced Interleukin (IL)-
10 serum release, while concomitantly inhibiting Tumor necrosis
factor (TNF)-α production “in vivo”(Bourrie et al., 1995, 1996;
Derocq et al., 1995). “In vitro” studies have shown that SR31747A
induces IL-10 and reduces nitric oxide synthesis in LPS-stimulated
macrophages (Gannon et al., 2001). In addition, SR31747 blocked
LPS-induced production of cytokines IL-1, IL-6, and TNFα in
a dose-dependent manner “in vitro” but not “in vivo” (Derocq
et al., 1995). SR31747 inhibits both delayed-type hypersensitivity
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granuloma and graft-versus-host reaction (Casellas et al., 1994).
Moreover, SR31747 impairs activation of T cells and reduces IFN-γ
and GM-CSF gene expression, while it barely alters IL-4 gene
expression (Carayon et al., 1995). SR125329A, a σ-1/σ-2 ligand,
which is also a human sterol isomerase ligand, inhibited staphy-
lococcal enterotoxin B-induced mouse splenocyte proliferation
(Bourrie et al., 2002) and enhanced LPS-induced systemic release
of IL-10 while simultaneously inhibiting TNF-α synthesis. It also
prevented graft-versus-host disease (Bourrie et al., 2002). Cocaine
has been reported to act as σ-1 receptor ligand being able to mod-
ulate immune function in vivo and in vitro (Pellegrino and Bayer,
1998; Xu et al., 1999). Thus, cocaine modulates cytokine produc-
tion by human peripheral blood lymphocytes, down-regulating
the production of IFN-γ, and IL-6 in leukocytes and increasing
the production of TGF-β by macrophages (Mattana et al., 1994;
Mao et al., 1996, 1997) and IL-10 by splenocytes (Zhu et al., 2003),
Nonetheless, some results suggest that the immunomodulatory
effects of cocaine may be mediated, in part, by modification of
endothelial-derived cytokine production (Mao et al., 1997). Thus,
although several reports have addressed the anti-inflammatory
and immunosuppressive activity of σ ligands in leukocytes, the
molecular mechanisms responsible for the actions of σ ligands
selective for the σ-1 or σ-2 receptor in T cells, remain unknown.
Activation of T cells triggers a complex regulatory cascade
of events leading to activation of transcription factors including
Nuclear Factor of Activated T Cells (NFAT) and Nuclear Factor
(NF)-κB, that culminates in the induced transcription of a variety
of activation-associated genes that in turn, regulate cell prolifera-
tion, differentiation, and acquisition of effectors functions by cells
of the immune system (Altman et al., 1990; Ullman et al., 1990;
Weiss and Littman, 1994). NFAT proteins are involved in the reg-
ulation of the transcriptional induction of a variety of genes that
are essential in the immune and inflammatory response such as
cytokines (IL-2, IL-4, IL-13, GM-CSF, TNFα), pro-inflammatory
genes (COX-2), and cell surface receptors (FasL, CD40L; Rao et al.,
1997; Crabtree, 1999; Iniguez et al., 2000).
Here, we have analyzed a panel of σ-1 and σ-2 ligands
(either agonists or antagonists) in T cell function in vitro
showing that treatment with σ-2 agonists interferes with T
cell activation and cytokine gene expression. Our findings
suggest that σ-2 agonists display immunomodulatory and
anti-inflammatory actions through the inhibition of NFAT-
dependent transcription, leading to down-regulation of T cell
activation.
MATERIALS AND METHODS
CELL CULTURE
The Jurkat human leukemic T cell line was grown in com-
plete RPMI 1640 medium, supplemented with 10% Fetal
Bovine Serum (FBS), 2 mM Glutamine and antibiotics. Puri-
fied human peripheral blood T lymphocytes (PBTs) were
obtained from partially purified human blood by Ficoll-
Hypaque gradient as previously described (Iniguez et al.,
1999). Cells were stimulated with Phorbol 12-myristate 13-
acetate (PMA; Sigma-Aldrich; 15 ng/ml), A23187 calcium
ionophore (Ion; Sigma); (1µM). Sigma ligands: PRE-O84 2-(4-
Morpholinethyl) 1-phenylcyclohexanecarboxylate (σ-1 agonist;
Tocris; Su et al., 1991); BD-1063 1-[2-(3,4-Dichlorophenyl)ethyl]-
4-methylpiperazine (σ-1 antagonist; Tocris; Matsumoto et al.,
1995); BD-737 (1S,2R)-cis-N -[2-(3,4-dichlorophenyl)ethyl]-N -
methyl-2-(1-pyrrolidinyl)-cyclohexylamine (Bowen et al., 1992)
and CB-184 -1R, 5R-(E)-8-(3,4-dichlorobenzylidene)-5-(3-
hydroxyphenyl)-2-methylmorphan-7-one (σ-2 agonists; Bowen
et al., 1995) and; AC-927 N-phenethylpiperidine oxalate (σ-2
antagonist; Berardi et al., 2004), were synthesized by Labora-
tories Esteve. These compounds were dissolved in DMSO and
tested over a range of concentrations (0.1–10µM). Cyclosporin
A (CsA, 100 ng/ml; Sigma-Aldrich) or σ ligands were added 1 h
prior PMA+ Ion stimulation.
mRNA ANALYSIS
Total RNA was prepared from cells by the TRIzol reagent
RNA protocol (Invitrogen). For standard RT-PCR, RNA (1µg)
was reverse transcribed by the RNA PCR core kit (Perkin-
Elmer). cDNA was used for PCR amplification to analyze
gene expression by standard RT-PCR using specific primers
for σ-1sense (5′-CTGGATGGGCGCCATGTG-3′); σ-1-antisense
T lymphocytes
IL-2
Jurkat cells
GAPDH
1 0
PMA+Ion
3 8 16 24Time (h) 
σ 1
1 0
PMA+Ion
3 6 12
σ 2
FIGURE 1 | Expression of σ receptors in humanT cells. RNA from Jurkat T
cells or human T lymphocytes stimulated with PMA (15 ng/ml)+ Ion (1µM) for
the indicated times (hours) was analyzed by RT-PCR to determine σ-1 and
σ-2/PGRMC1 receptors, IL-2 or GAPDH mRNA levels. An aliquot of the
amplified DNA was separated on an agarose gel and stained with ethidium
bromide for qualitative comparison.
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(5′-GGCCAAAGAGGTAGGTGG-3′); σ-2/PGRMC1-sense (5′-
ATCATGGCTGCCGAGGATGTG-3′);σ-2/PGRMC1-antisense (5′-
GAGGTCAGAAAGGTCATCGTAC-3′).
GAPDHsense (5′-TGGCAAATTCCATGGCA-3′); GAPDHan-
tisense (5′-TCTAGACGGCAGGTCAGGTCCACC-3′); IL-2sense
(5′-ATGTACAGGATGCAACTCCTGTCTT-3′); IL-2antisense (5′-
GTCAGTGTTGAGATGATGCTTTGAC-3′).
PCR reaction was amplified by 25–30 cycles of denaturation
at 94˚C for 45 s, annealing at 55 or 60˚C for 45 s, and extension
at 72˚C for 45 s. PCR products were separated on agarose gel
electrophoresis and visualized by ethidium bromide staining.
For quantitative real-time RT-PCR analysis, total RNA was
reversed transcribed using the components of the High Capac-
ity cDNA Archive Kit (Applied Biosystems). Amplification of
cDNAs was performed using the TaqMan Universal PCR Master
Mix (Applied Biosystems) on an ABI PRISM 7900HT instru-
ment (Applied Biosystems) for 40 cycles with specific primers
and Taqman MGB probes for IL-2, TNFα, COX-2, and GAPDH.
(Applied Biosystems). All samples were run in triplicate. Quan-
tification of gene expression by real-time RT-PCR was calculated
by the comparative threshold cycle (∆∆CT) method following
the manufacturer’s instructions. Relative quantification (RQ) of
mRNA levels was determined using endogenous expression of
GAPDH and is shown in all the experiments as RQ± standard
deviation (SD).
TRANSFECTION AND LUCIFERASE ASSAYS
Luciferase reporter assays in Jurkat cells were performed by tran-
sient transfection of different plasmids in exponential growing
cells (1× 106 cells/ml in OPTIMEM medium) by the Lipofecta-
mine 2000 reagent (Invitrogen). After 4 h of incubation, RPMI
medium containing 5% FBS was added to cells and the incuba-
tion was continued for 16 h to complete transfection. Cells were
treated with increasing doses of the indicated compounds for 1 h
prior to treatment with PMA (15 ng/ml)+ Ion (1µM) for addi-
tional 5 h. Luciferase activity was determined in cell lysates with a
luciferase assay kit (Promega) with a luminometer Monolight 2010
(Analytical Luminescence Laboratory). Results are represented
as percentage of activity, considering 100% that obtained in the
PMA+ Ion stimulated samples, and are shown as the mean± SD
from triplicate assays.
Human COX-2 promoter construct COX-2-Luc (p2-1900) has
been described previously (Iniguez et al., 1999). The IL-2-LUC
plasmid contains the region spanning from −326 to+ 145 of
the human IL-2 promoter (Durand et al., 1988). The plasmid
TNFα-LUC contains a region 1311 bp upstream from the tran-
scriptional initiation site of human TNFα promoter (Rhoades
et al., 1992). The NFAT-LUC reporter construct contains three
tandem copies of the distal NFAT binding site fused to the IL-2
minimal promoter (Durand et al., 1987). NF-κB luciferase reporter
contains three tandem repeats of the NF-κB-binding site from the
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FIGURE 2 | Effects of σ-1 ligands onTNFα and IL-2 production by
activated JurkatT cells. Jurkat cells were treated for 16 h with PMA
(15 ng/ml)+ Ion (1µM) in the presence of different concentrations (1, 5,
and 10µM) of the σ-1 agonist PRE-O84 or the antagonist BD-1063. Levels
of TNFα (A) and IL-2 (B) released into the medium were measured by an
ELISA assay.
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Igκ promoter located upstream of a minimal conalbumin pro-
moter controlling the luciferase gene (Arenzana-Seisdedos et al.,
1993).
CYTOKINE MEASUREMENT
The concentration of IL-2 and TNFα in supernatants of Jurkat
cell cultures was determined using specific ELISAs in the presence
or absence of σ ligands. Commercially available kits were used
according to manufacturer’s instructions (Bender MedSystems).
Cytokine concentration was assayed in triplicate.
PROSTAGLANDIN E2 MEASUREMENT
To evaluate PGE2 production in Jurkat cells after the different
treatments, the media was aspirated and cells rinsed with HBS, pH
7.4, supplemented with 0.1% BSA. Then, cells were incubated for
30 min at 37ºC in the same buffer with an excess of AA (10µM).
Levels of PGE2 were determined in the supernatants using a PGE2
enzyme immunoassay kit (Cayman Chemical). All samples were
tested in triplicate.
IMMUNOBLOT ANALYSIS
Total extracts of Jurkat cells were obtained after lysis for
30 min in ice-cold lysis buffer (Phosphate-buffered saline, 1%
Non-idet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mM
phenylmethylsulphonyl fluoride, 2µg/ml aprotinin, 2µg/ml leu-
peptin, and 1µg/ml pepstatin, 1 mM sodium orthovanadate and
1 mM sodium fluoride). Lysates were denatured and resolved
by SDS-polyacrylamide gel electrophoresis and then transferred
to nitrocellulose membranes. The filters were incubated with
anti-NFAT antisera (anti-NFATc2 #672; 1:3000; generous gift
of Dr. J. M. Redondo) that recognize both the dephosphory-
lated and phosphorylated forms of NFAT (San-Antonio et al.,
2002; Jimenez et al., 2004). β-actin levels were determined as
a control of loading in each lane with a specific antibody
(Santa Cruz Biotechnology). After incubation with a goat anti-
rabbit IgG secondary antibody linked to horseradish peroxidase
(Pierce) at 1:15000 dilution, the stained bands were visualized
with the ECL (enhanced chemiluminescence) detection reagent
(Pierce).
STATISTICS
Results are expressed as mean± SD from at least three indepen-
dent experiments performed by duplicate or triplicate. Statistical
analysis was carried out by the Student t -test with p< 0.05 rep-
resenting significance. Statistical analyses were done using Graph
Pad software.
RESULTS
EXPRESSION OF THE σ RECEPTORS IN HUMAN T LYMPHOCYTES
Expression of the σ-1 and σ-2/PGRMC1 receptors mRNAs in
human T cells was analyzed by RT-PCR. As shown in Figure 1, con-
stitutive expression of theσ-1 andσ-2/PGRMC1 receptors mRNAs
were detected in Jurkat T cell line and in primary lymphocytes
isolated from human blood. Expression of these receptors did not
seem to be influenced by activation of the cells with the phorbol
ester PMA+ the Ca++ ionophore A23187 (Ion) at any of the times
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FIGURE 3 | Inhibition ofTNFα and IL-2 production by σ-2 agonists in
activated JurkatT cells. Jurkat cells were treated for 16 h with PMA
(15 ng/ml)+ Ion (1µM) in the presence of different concentrations (1, 5, and
10µM) of the σ-2 agonists BD-737 and CB-184 or the antagonist AC-927.
Levels of TNFα (A) and IL-2 (B) released into the medium were measured by
an ELISA assay. (n.s, not significant; *p<0.05; **p<0.01 versus PMA+ Ion).
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analyzed. This pharmacologic treatment is known to mimic T cell
receptor activation (TCR) in T cells. IL-2 mRNA expression was
induced in a time-course dependent manner, which serves as a
control of gene transcriptional induction upon T lymphocyte acti-
vation. Levels of GAPDH mRNA are shown as a control of loading.
These results indicate that both σ-1 and σ-2/PGRMC1 receptors
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FIGURE 4 | Effect of σ-2 ligands on the expression of IL-2,TNFα, and
COX-2 in JurkatT cells. (A)Total RNA from Jurkat cells, treated with
σ-2 agonists BD-737 and CB-184 or the antagonist AC-927 at the doses
indicated (1, 5, and 10µM) and grown in the absence or presence of
PMA (15 ng/ml)+ Ion (1µM), was analyzed by quantitative RT-PCR.
Relative quantification (RQ) of mRNA levels of IL-2, TNFα, and COX-2
was determined using endogenous expression of GAPDH and is
shown as RQ±SD. (B) PGE2 production by Jurkat cells treated with
σ-2 agonists BD-737 and CB-184 at the doses indicated (1 and 10µM),
grown in the absence or presence of PMA+ Ion. PGE2 was measured
by a standard EIA assay as described in Section “Materials and
Methods.” Results are shown as the mean±SD of PGE2 in pg/ml of
determinations conducted in triplicate. (n.s, not significant; *p<0.05;
**p<0.01 versus PMA+ Ion).
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FIGURE 5 | Inhibitory effect of σ-2 agonists on the activity of IL-2,TNFα,
and COX-2 promoters in JurkatT cells. Jurkat cells were transiently
transfected with luciferase reporter constructs containing the promoter
regions of the IL-2 (A), TNFα (B), or COX-2 (C) genes and treated for 6 h with
PMA (15 ng/ml)+ Ion (1µM) in the absence or presence of increasing doses
(0.1, 1, and 5µM) of σ-2 ligands BD-737 and CB-184 (σ-2 agonists) or AC-927
(σ-2 antagonist) as indicated. Luciferase activity was measured and
represented in percentage of activity considering 100% the activity obtained
upon PMA+ Ion stimulation in the absence of σ ligand. (n.s, not significant;
*p<0.05; **p<0.01 versus PMA+ Ion).
are constitutively expressed in human T lymphocytes but they are
not modulated by TCR activation.
EFFECT OF σ-1 AND σ-2 LIGANDS ON CYTOKINE PRODUCTION IN T
CELLS
Activated T cells produce a variety of cytokines such as IL-2
and TNF-α, among others. The coordinated production of these
cytokines is crucial for regulation of the inflammatory response.
We evaluated the immunomodulatory actions of increasing doses
of σ ligands on the production of IL-2 and TNFα by activated
Jurkat cells. Both selective σ-1 agonist PRE-084 (K i values of 2.2
and 13091 nM for σ-1 and σ-2 receptors respectively; Su et al.,
1991; Rossi et al., 2011) and σ-1 antagonist BD-1063 (K i value of
9 nM for the σ-1 receptor and more than 49 times selectivity over
the σ-2 receptor; Matsumoto et al., 1995; Entrena et al., 2009),
were used to determine the effect of σ-1 ligands in these cells. As
shown in Figure 2, neither the σ-1 agonist PRE-084 nor the σ-1
antagonist BD-1063 showed a significant effect on the induction of
the production of IL-2 or TNFα in Jurkat T cells upon stimulation
with PMA+ Ion.
We next evaluated the effects of different σ-2 ligands in these
cells: CB-184, described as a selective σ-2 receptor agonist with
554-fold selectivity for σ-2 receptors over σ-1 (Bowen et al., 1995;
Vilner and Bowen, 2000; Crawford et al., 2002); BD-737, a potent
σ receptor ligand with properties as σ-2 ligand (Bowen et al.,
1992; Vilner and Bowen, 2000; Crawford et al., 2002); and the
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σ-2 receptor antagonist AC927 (Crawford et al., 2002; Berardi
et al., 2004; Matsumoto et al., 2008). Different to σ-1 ligand, both
σ-2 agonists, BD-737, and CB-184, produced a dose-dependent
decrease in the PMA+ Ion-mediated induction of IL-2 or TNFα
production, with the strongest effect observed after treatment with
CB-184. The σ-2 antagonist AC-927 did not show a significant
effect at any of the doses assayed (Figure 3).
To determine whether the effects of sigma ligands on cytokine
production were a consequence of changes in mRNA expression,
we performed quantitative real-time RT-PCR assays, analyzing
mRNA levels of these cytokines as well as of another gene involved
in inflammation as cyclooxygenase (COX)-2. In agreement to
the above results, increasing doses of σ-2 agonists significantly
diminished the induction by PMA+ Ion of TNFα, IL-2, or COX-2
mRNAs (Figure 4A). No effect of the σ-2 antagonist AC-927 was
observed. The inhibitory effects of these σ-2 agonists on COX-
2 expression correlated with those observed with COX activity.
Thus, BD-737 and CB-184 produced a dose-dependent decrease in
the PMA+ Ion-mediated induction of PGE2 production in Jurkat
cells (Figure 4B).
Changes in mRNA levels can take place by the influence of these
ligands on transcriptional induction, so we next investigated the
regulation of TNFα, IL-2, and COX-2 promoters in Jurkat cells. As
shown in Figure 5, treatment with PMA+ Ion induced a substan-
tial increase in the transcriptional induction mediated by these
promoters in Jurkat T cells. Treatment with σ-2 agonists, BD-737,
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FIGURE 6 | Effect of σ-1 ligands on the activity of IL-2,TNFα, and
COX-2 promoters in JurkatT cells. Jurkat cells were transiently
transfected with luciferase reporter constructs containing the
promoter regions of the IL-2 (A), TNFα (B), or COX-2 (C) genes and
treated for 6 h with PMA (15 ng/ml)+ Ion (1µM) in the absence or
presence of increasing doses (0.1, 1, and 5µM) of the σ-1 agonist
PRE-084 or σ-1 antagonist BD-1063 as indicated. Luciferase activity
was measured and represented in percentage of activity considering
100% the activity obtained upon PMA+ Ion stimulation in the
absence of σ ligand.
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and CB-184, but not with the σ-2 antagonist AC-927, was able to
severely impair transcriptional activation mediated by PMA+ Ion
in Jurkat T cells. Again, no changes in the activity of these promot-
ers upon PMA+ Ion were observed by treatment with σ-1 ligands
(Figure 6).
EFFECTS OF σ-1 AND σ-2 LIGANDS ON NF-κB AND NFAT-DEPENDENT
TRANSCRIPTIONAL ACTIVATION IN T CELLS
Transcriptional activation of a variety of genes induced upon T
cell activation, including TNF-α, IL-2, and COX-2, depends on
the coordinate interactions among several transcription factors,
including members of NF-κB, and NFAT families (Rao et al.,
1997; Crabtree, 1999). To determine whether inhibition of gene
expression was occurring through the action of σ ligands on the
activation of these transcription factors, we evaluated the effect
of these compounds on the activity of NF-κB and NFAT by using
luciferase reporter gene constructs including minimal promoters
under the control of NFAT or NF-κB-binding sites. Treatment with
PMA+ Ion promoted an important increase in the activity of both
NF-κB-LUC and NFAT-LUC reporter constructs in Jurkat T cells.
Figures 7A,B shows the results obtained with the σ-2 agonists
BD-737 and CB-184 and σ-2 antagonist AC-927. Sigma-2 agonists
treatment displayed a profound inhibitory effect on transcrip-
tional activation mediated by both NF-κB and NFAT. In contrast,
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FIGURE 7 | Effect of σ-2 ligands on transcriptional induction mediated by
NF-κB and NFAT in JurkatT cells. Jurkat cells were transiently transfected
with the luciferase reporter constructs NF-κB-LUC (A) or NFAT-LUC (B) and
treated for 6 h with PMA (15 ng/ml)+ Ion (1µM) in the absence or presence
of increasing doses (0.1, 1, and 5µM) of σ-2 agonists (BD-737 and CB-184) or
antagonist (AC-927). (C) Cells transfected with the NFAT-LUC plasmid and
treated with PMA+ Ion were treated with σ-2 agonists BD-737 (5µM) or
CB-184 (0.5µM) in the absence or presence of increasing doses of σ-2
antagonist AC-927 (0.5 and 1µM). Luciferase activity was measured and
represented in percentage of activity considering 100% the activity obtained
upon PMA+ Ion stimulation in the absence of σ ligands. (n.s, not significant;
*p<0.05; **p<0.01 versus PMA+ Ion).
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σ-2 antagonist AC927 or σ-1 ligands PRE-084 and BD-106 did not
exhibit any significant effect on the activity of these transcription
factors (Figures 7 and 8).
Inhibitors of NFAT activation as Cyclosporine A or Tacrolimus
are well-known immunomodulatory drugs with a potent
immunosuppressive effect (Kiani et al., 2000; Martinez-Martinez
and Redondo, 2004). The above results pointed to σ-2 agonists
as able to interfere with NFAT-dependent transcriptional activa-
tion of gene expression. To further confirm the specificity of the
actions of σ-2 agonists on NFAT activation, we tested whether a
σ-2 antagonist could block this effect. As shown in Figure 7C, the
inhibitory effect of both BD-737 and CB-184 on NFAT-LUC was
reversed in a dose-response manner by the σ-2 antagonist AC-
927. To address the mechanism involved in the actions of these
compounds on NFAT-dependent transcription, we next analyzed
the effect of these compounds on NFAT phosphorylation. In rest-
ing T cells, NFAT is a cytoplasmic factor that upon activation
is dephosphorylated by the calcineurin phosphatase and translo-
cated into the nucleus leading to transactivation of target genes
(Rao et al., 1997; Crabtree, 1999; Hogan et al., 2003). As shown in
Figure 9, upon activation with PMA+ Ion NFAT is dephospho-
rylated, showing a decrease in phosphorylated NFAT signal and
an increase in a band of dephosphorylated NFAT, which migrates
faster in SDS-PAGE. Both BD-737 and CB-184 partially inhibited
in a dose-dependent manner the dephosphorylation of NFAT. In
contrast, AC 927 had no effect. As a control it is shown the inhi-
bition of calcineurin phosphatase activity by Cyclosporin A (CsA)
and hence, NFAT dephosphorylation, which is known to result in
a complete prevention of nuclear translocation of NFAT (Kiani
et al., 2000; Martinez-Martinez and Redondo, 2004). This result
pointed to σ-2 agonists as inhibitor of NFAT signaling, interfering
with the early steps in the activation of this factor.
Taken together, our results support an inhibitory role of NFAT-
mediated transcriptional activation in Jurkat T cells by the σ-2
agonists BD-7373 and CB-184, which, in addition to inhibition of
NF-κB activation, could account for the inhibitory actions on the
transcriptional induction and expression of activation-induced
genes such as TNFα, IL-2, and COX-2.
DISCUSSION
In this report we have analyzed the effect of σ ligands on T cell
function. Our results show a novel pharmacological activity of
sigma-2 ligands on the immune system. Namely, σ-2 agonists
have immunosuppressive activity in T lymphocytes. On the other
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FIGURE 8 | Effect of σ-1 ligands on transcriptional induction mediated by
NF-κB and NFAT in JurkatT cells. Jurkat cells were transiently transfected
with the luciferase reporter constructs NF-κB-LUC (A) or NFAT-LUC (B) and
treated for 6 h with PMA (15 ng/ml)+ Ion (1µM) in the absence or presence
of increasing doses (0.1, 1, and 5µM) of the σ-1 agonist (PRE-084 and
CB-184) or antagonist (AC-927). Luciferase activity was measured and
represented in percentage of activity considering 100% the activity obtained
upon PMA+ Ion stimulation in the absence of σ ligands.
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FIGURE 9 | Actions of σ 2 ligands on NFAT dephosphorylation. Protein
extracts from Jurkat treated with PMA (15 ng/ml)+ Ion (1µM) for 2 h in the
presence or absence of increasing doses (2.5, 10, and 25µM) of σ-2
agonists (BD-737 and CB-184) or antagonist (AC-927) were analyzed by
Western blot with an anti-NFAT serum. The phosphorylated (NFAT-P) and
dephosphorylated (NFAT-dP) forms of NFATc2 are indicated by arrows.
Inhibition of NFAT dephosphorylation by Cyclosporin A (CsA) is shown as a
control. β-Actin protein levels were determined as a control of loading.
hand, signaling through the σ-1 receptor, at least by the results
obtained with the selected σ-1 agonists or antagonists, does not
seem to exert evident functional consequences on the immune
activation parameters assayed. We found that basal levels of σ-
1 receptor mRNA are present in resting human T cells that do
not change upon T cell activation. A similar profile of expression
was observed with the recently described putative σ-2 receptor
PGRMC1 (Xu et al., 2011). Expression of this receptor has been
described in peripheral blood cells and T lymphocytes, being ele-
vated in multiple tumor types (Mir et al., 2012; Ndiaye et al., 2012).
The existence of a σ binding site in the Jurkat human T cell line
corresponding to an alternatively spliced σ-1 receptor variant has
been previously described (Ganapathy et al., 1999). Nonetheless,
pharmacology of the sigma binding site in Jurkat T cells seems to
be consistent with the σ-2 receptor subtype (DeHaven-Hudkins
et al., 1996).
Several reports have described anti-inflammatory and
immunoregulatory properties of σ ligands both “in vitro” and
“in vivo” (Casellas et al., 1994; Bourrie et al., 1995, 2002; Carayon
et al., 1995; Derocq et al., 1995; Liu et al., 1995; Gannon et al.,
2001; Zhu et al., 2003). However the exact biological signifi-
cance and the nature of σ receptor signaling mediating these
effects are poorly understood. Several of the anti-inflammatory
and immunosuppressive effects of sigma ligands in immune cells
have been suggested to be indirect, due to their ability of these
compounds to induce anti-inflammatory cytokines as TGFβ or
IL-10 (Bourrie et al., 1995; Zhu et al., 2003; Kvaratskhelia et al.,
2009) or even by promoting glucocorticoid-dependent immuno-
suppression (Derocq et al., 1995). Moreover, controversial data
about the identification of these effects as selectively dependent
on σ-1 or σ-2 exist. There is a lack of consistency between phar-
macology of σ binding selectivity and the immunomodulatory
events observed in response to σ ligands. These discrepancies may
be due to the different σ compounds used or to the fine speci-
ficity of those ligands for different unidentified target receptors
in immune cells. Kvaratskhelia et al. (2009) have reported that σ-
ligands can modulate IL-8 and IL-10 production by T cells through
modulation of the NMDA Glutamate Receptor. Particularly, very
little is known about the pharmacology of σ-2 receptors and the
effect of ligands acting specifically through this receptor. The fact
that the real nature of the σ-2 receptor has not been clearly deter-
mined has prevented further analysis. Signaling cascades directly
coupled to activation of this receptor have not yet been identified
and only some data is available on its function.
Here we provide some new data on σ-2 receptor function and
signaling. Thus, we have found that the σ-2 receptor agonists BD-
737 and CB-184 had an interesting behavior compatible with
being immunosuppressive and anti-inflammatory drugs. Since
our results show that two σ-2 receptor agonists with different
chemicals properties have a similar effect which is reversed by
a σ-2 antagonist, it is likely that a putative σ-2 receptor binding
site participates in the observed effect in T lymphocytes. In con-
trast to σ-1 compounds, here, we have shown that σ-2 agonists
but not just a merely σ-2 ligand as the σ-2 antagonist AC927 are
able to decrease T cell activation “in vitro”. Those two σ-2 ago-
nist compounds of different chemical structure inhibited COX-2,
TNFα, and IL-2 mRNA as well as cytokine release by activated
T cells. Those effects seem to occur through inhibition of tran-
scriptional activation of these genes as σ-2 agonists were able to
diminish the PMA+ Ion-mediated induction of the activity of
TNFα, IL-2, and COX-2 promoters in T cells. This effect takes place
at the transcriptional level, reducing NFAT and NF-κB activation.
We present evidence showing that BD-737 and CB-184 inhibited
PMA+ Ion-mediated activation of NFAT, altering its dephospho-
rylation and hence nuclear shuttling and NFAT-mediated gene
transcription. Interestingly, the effects on NFAT-dependent tran-
scription can be prevented by a σ-2 antagonist, further confirming
the specificity of action. NFAT proteins play an important role
in many cellular processes being involved in the regulation of the
expression of a variety of T cell cytokines (IL-2, IL-4, IL-5, IL-6,
IL-8, IL-13, IFN-γ, TNF-α) essential for the immune response and
inflammation (Rao et al., 1997; Crabtree, 1999; Hogan et al., 2003).
Thus, inhibition of NFAT activation by σ-2 agonist may explain
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their effects on transcriptional regulation of NFAT-dependent
genes. Furthermore, our results show that the σ-2 agonists eval-
uated inhibited NFAT dephosphorylation, an essential step for
NFAT activation and entry into the nucleus (Rao et al., 1997; Crab-
tree, 1999; Hogan et al., 2003). Treatment with increasing doses of
σ-2 agonist causes NFAT to be maintained in a phosphorylated
state and hence block the nuclear translocation of NFAT and, thus
NFAT-dependent gene transcription. Whether this effect is occur-
ring by a mechanism involving interference on Ca++ signaling or
calcineurin phosphatase activity as in the case of the well-known
NFAT inhibitors CsA and Tacrolimus (Kiani et al., 2000; Martinez-
Martinez and Redondo, 2004), remains to be elucidated. Besides,
NFAT activation plays a promoting role in cancer (Duque et al.,
2005; Viola et al., 2005; Gachet and Ghysdael, 2009). Thus, it is
tempting to speculate that some of the effects of σ-2 agonists on
cancer may take place though NFAT inhibition. Further studies
are needed to elucidate this hypothesis.
In summary, our results show that σ-2 agonist-ligands have
an important immunosuppresor and anti-inflammatory effect
inhibiting T cell activation at relevant pharmacological doses by
blocking transcriptional activation through their interference with
NF-κB and especially NFAT activation. Nonetheless, our data will
not necessarily predict the effects of σ-2 agonists in vivo, further.
Therefore, these data open a new field for the study of σ-2 lig-
ands as new therapeutic agents in pathologies as inflammatory and
autoimmune diseases. In addition, they also open new answers to
explore the therapeutic effect of σ-2 agonists on other diseases
where NFAT inhibition may play a pathological role.
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